Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Renal Insufficiency 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Leukemia 1Kidney Neoplasms 1Hematologic Diseases 1Carcinoma, Renal Cell 1Breast Neoplasms 1Brain Neoplasms 1Blood Protein Disorders 1

Interventions

Sunitinib 64Nivolumab 54Sorafenib 38Bevacizumab 35Axitinib 35pembrolizumab 34Everolimus 30cabozantinib 29pazopanib 26aldesleukin 26Ipilimumab 23Interleukin-2 19Specimen Handling 17Magnetic Resonance Spectroscopy 17Gemcitabine 17lenvatinib 16Interferon-alpha 15Interferon alpha-2 13Radiosurgery 12Cyclophosphamide 12fludarabine phosphate 11atezolizumab 10durvalumab 8Introns 8Erlotinib Hydrochloride 8Biopsy 8temsirolimus 7avelumab 7Radiotherapy 7Capecitabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Renal Cell × Ranitidine × Clear all
NCT00030992 2012-08-20

BMS 247550 to Treat Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
102 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡